Disclosure of Genetic Risk for Alzheimer's Disease

Research Type: 
Alzheimer's Disease

Background

Susceptibility testing for Alzheimer’s disease provides an instructive paradigm in which to examine genetic testing for a common, complex disease. The Disclosure of Genetic Risk for Alzheimer's Disease Study applies innovative social and behavioral methods to analyze the process of risk disclosure for Alzheimer’s disease susceptibility rigorously and to increase our understanding of how these processes relate to the ultimate impact of genetic risk assessment.

Study Aims

The Roter Interactional Analysis System (RIAS) coding method will be applied to audiotaped provider-patient interactions during Alzheimer’s disease risk disclosure sessions that occurred as part of the REVEAL Study to achieve the following aims:

To examine how provider-patient interactions predict key patient and provider outcomes such as distress, accurate risk recall and satisfaction
To examine differences in provider-patient interactions when negative test results are disclosed versus positive test results
To explore the impact of provider and patient characteristics on provider-patient interactions and patient outcomes.

Funding Source

The Disclosure of Genetic Risk for Alzheimer's Disease Study is funded by an R03 grant from the National Institutes of Health.

Key Personnel

J. Scott Roberts, Ph.D., Principal Investigator 

Debra Roter, Dr.PH, Co-Principal Investigator, Johns Hopkins

Barbara Lerner, Co-Investigator, Boston University